Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $700,000.

  • SAB Biotherapeutics' Depreciation & Amortization (CF) fell 22.22% to $700,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 37.08%. This contributed to the annual value of $4.7 million for FY2024, which is 27.18% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Depreciation & Amortization (CF) is $700,000, which was down 12.50% from $800,000 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Depreciation & Amortization (CF) ranged from a high of $2.0 million in Q1 2024 and a low of $235,959 during Q1 2021.
  • For the 3-year period, SAB Biotherapeutics' Depreciation & Amortization (CF) averaged around $975,618, with its median value being $900,000 (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 189.70% in 2022, then crashed by 60.00% in 2025.
  • SAB Biotherapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $619,984 in 2021, then soared by 49.90% to $929,379 in 2022, then rose by 4.30% to $969,340 in 2023, then declined by 21.18% to $764,007 in 2024, then fell by 22.22% to $700,000 in 2025.
  • Its last three reported values are $700,000 in Q3 2025, $800,000 for Q2 2025, and $800,000 during Q1 2025.